This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
stock-price-change: Archive
Earnings Preview: HudBay Minerals (HBM) Q3 Earnings Expected to Decline
by Zacks Equity Research
HudBay Minerals (HBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HBMPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Earnings Preview: RMR Group (RMR) Q4 Earnings Expected to Decline
by Zacks Equity Research
RMR Group (RMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RMRNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALVONegative Net Change IRDNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Nu Holdings Ltd. (NU) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Nu (NU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NUPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Here's Why Vital Farms (VITL) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Vital Farms (VITL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
VITLNegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
CELZPositive Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VRDNPositive Net Change IVVDPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Plug Power (PLUG) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Plug Power (PLUG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLUGNegative Net Change ROKPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Sky Harbour Group Corporation (SKYH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Sky Harbour Group (SKYH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKYHNegative Net Change RKLBPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
SKYX Platforms Corp. (SKYX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
SKYX PLATFORMS (SKYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKYXNegative Net Change BTDRNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OBIONegative Net Change ZYMEPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ondas Holdings Inc. (ONDS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ondas (ONDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ONDSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OVIDPositive Net Change RNANo Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOLTPositive Net Change PTGXPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FATEPositive Net Change ARCTPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
HIVE Digital Technologies (HIVE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
HIVE Digital Technologies (HIVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HIVEPositive Net Change WULFPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate CAE (CAE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CAE (CAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAEPositive Net Change DCOPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Evolution Petroleum (EPM) Reports Next Week: What You Should Expect
by Zacks Equity Research
Evolution Petroleum (EPM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EPMNo Net Change MNRNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRDNegative Net Change CERTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Somnigroup International (SGI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Somnigroup International (SGI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
SGIPositive Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Here's Why BRP (DOOO) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
BRP (DOOO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
DOOONegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Century Communities (CCS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Century Communities (CCS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CCSNegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Humana (HUM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Humana (HUM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
HUMNegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Capri Holdings (CPRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Capri Holdings (CPRI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
CPRINegative Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement
Scor (SCRYY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Scor (SCRYY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
SCRYYPositive Net Change
momentum-investor momentum-stocks stock-price-change stock-price-movement